<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275925</url>
  </required_header>
  <id_info>
    <org_study_id>CTRI476BRU01</org_study_id>
    <nct_id>NCT00275925</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures</brief_title>
  <official_title>A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine
      monotherapy in adults with partial seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epileptic activity at electroencephalography in rest</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Flash light and hyperventilation test with electroencephalography</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of epileptic episodes according to patient's diary</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram analysis for rhythm and conduction</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood test for sodium, hepatic enzymes and blood cells</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment at baseline, last visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of 24 week's treatment with oxcarbazepine monotherapy in adult patients with partial seizures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with total and partial control of epilepsy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients requiring additional antiepileptic drugs</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Epilepsy, Partial Seizures</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females, 18 - 70 years of age;

          -  diagnosis of epilepsy, partial seizures;

          -  ineffective or intolerable present therapy with 1 antiepileptic drug, or none of
             previous therapy with antiepileptic drugs

        Exclusion Criteria:

          -  progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years
             prior to screening;

          -  non-epileptic seizures;

          -  drug or alcohol dependence during a year prior to screening;

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epilepsy Department of the Moscow Research Institute of Psychiatry</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neurosurgery Department of the Moscow State Medico-stomatology University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neurosurgery Department of the Russian State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department of I.M. Sechenov Moscow Medical Academy</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department of Pediatric faculty of the Russian State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department of the Moscow region Research Institute named after M.F. Vladimirskiy</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epilepsy Department of the V.M. Bekhterev Sant-Petersburg Psychoneurology Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <last_update_submitted>November 29, 2007</last_update_submitted>
  <last_update_submitted_qc>November 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2007</last_update_posted>
  <keyword>partial epilepsy, oxcarbazepine, adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

